COMP <GO>
BMY vs VRTX // EV/EBITDA & P/E VALUATION
Bristol-Myers Squibb Company (NYSE) VS. Vertex Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: BMY 4
— VRTX 10
▲ EV/EBITDA & P/E VALUATION LEADER: BMY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
valuation
16.3x
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
valuation
29.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. VRTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | VRTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | 86.20% | -15.10 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 20.00% | -6.70 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.3x | 29.6x | -13.30 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 2.33% | +7.91 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 34.80% | -16.90 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 32.90% | -18.30 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 8.90% | -9.10 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 0.00% | +4.02 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 13.86 | -11.62 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 57.7 | -7.30 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.02 | -0.04 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 32.2x | -15.60 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $136.87B | -$11.47B | VRTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | VRTX REV | BMY GROSS % | VRTX GROSS % | BMY FCF | VRTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | $12.00B | 71.1% | 86.2% | $12.85B | $3.19B |
| FY 2024 | $48.30B | $11.02B | 71.1% | 86.1% | $13.94B | -$790.3M |
| FY 2023 | $45.01B | $9.87B | — | — | $11.83B | $3.09B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
VRTX // BETA 1.02